![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
L Bjork, LJ Cornfield, DL Nelson, SE Hillver, NE Anden, T Lewander and U Hacksell
Department of Medical Pharmacology, Uppsala Biomedical Centre, Uppsala University, Sweden.
The selective 5-hydroxytryptamine (5-HT1A) receptor agonist 8-hydroxy-2- (dipropylamino)tetralin (8-OH-DPAT) induces a large number of pharmacological effects. In the present study we demonstrate that a novel 8-OH-DPAT analog, (S)-5-fluoro-8-hydroxy-2- (dipropylamino)tetralin [(S)-UH-301], is able to antagonize completely the following (R)-8-OH-DPAT-induced effects in the rat: 1) reduction in brain 5-HT biosynthesis, measured as a decreased 5-hydroxytryptophan- accumulation after decarboxylase inhibition; 2) induction of the 5-HT1A behavior (flat body posture, forepaw treading and hindlimb abduction) in reserpine-pretreated animals; 3) reduction of body temperature; 4) inhibition of the cage-leaving response; and 5) reduction of 5- hydroxytryptophan- and quipazine-induced wet dog shakes. In addition, (S)-UH-301 reverses the 5-HT-induced inhibition of the forskolin stimulated cyclic AMP production in rat hippocampus without producing any effects per se in this assay. It is shown that high doses of (S)-UH- 301 decrease rat brain biosynthesis of dopamine. These and previous data indicate that (S)-UH-301 also is a weakly potent dopamine-receptor agonist, but with a lower affinity for D2 as compared to 5-HT1A receptors. Thus, the data suggest that (S)-UH-301 is a 5-HT1A-receptor antagonist without intrinsic activity. Therefore, it is likely that (S)- UH-301 will become a valuable pharmacological tool in future 5-HT research.
This article has been cited by other articles:
|
|
 |
|
  L. P. Martin, D. M. Jackson, C. Wallsten, and B. L. Waszczak Electrophysiological Comparison of 5-Hydroxytryptamine1A Receptor Antagonists on Dorsal Raphe Cell Firing J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 820 - 826. [Abstract] [Full Text]
|
|
|
|
|
|
N. A. Darmani and B. Ahmad Long-Term Sequential Determination of Behavioral Ontogeny of 5-HT1A and 5-HT2 Receptor Functions in the Rat J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 247 - 253. [Abstract] [Full Text]
|
|
|
|
|
|
L. Johansson, D. Sohn, S.-O. Thorberg, D. M. Jackson, D. Kelder, L.-G. Larsson, L. Rényi, S. B. Ross, C. Wallsten, H. Eriksson, et al. The Pharmacological Characterization of a Novel Selective 5-Hydroxytryptamine1A Receptor Antagonist, NAD-299 J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 216 - 225. [Abstract] [Full Text]
|
|
|
|
|
|
D. L. Willins and H. Y. Meltzer Direct Injection of 5-HT2A Receptor Agonists into the Medial Prefrontal Cortex Produces a Head-Twitch Response in Rats J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 699 - 706. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
